Holen Sie sich die Stockscreener-App
3.99
3.62%
-0.15
Handel nachbörslich:
4.00
0.010
+0.25%
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
Exit Recap: Why is AbCellera Biologics Inc stock going downJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Can AbCellera Biologics Inc disrupt its industry2025 Winners & Losers & Free High Return Stock Watch Alerts - baoquankhu1.vn
Strategic Moves Shape ABCL’s Market Position - StocksToTrade
AbCellera’s Market Moves: Key Developments - timothysykes.com
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Rating of "Hold" by Brokerages - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Trading Down 6.1%Here's Why - MarketBeat
Is AbCellera Biologics Inc a top pick in the sectorPortfolio Value Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
AbCellera Biologics Inc. (ABCL) Stock Analysis: Exploring a Promising 111.93% Potential Upside - directorstalkinterviews.com
AbCellera Biologics (NASDAQ:ABCL) Trading Up 11.6%Here's Why - MarketBeat
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 - Investing News Network
A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Advances Into Phase 2 Trial - Sahm
AbCellera Biologics (NASDAQ:ABCL) Stock Rating Lowered by Wall Street Zen - MarketBeat
Why AbCellera Biologics Inc. stock could rally in 2025High Dividend Yield Stocks & Invest Like A Pro - bollywoodhelpline.com
Is AbCellera (ABCL) Quietly Recasting Its Platform As A Menopause-Focused Drug Developer? - simplywall.st
Aug Reactions: What is the implied volatility of Sonida Senior Living IncMarket Movers & Weekly Hot Stock Watchlists - baoquankhu1.vn
Citizens Financial Group Inc. RI Acquires Shares of 261,890 AbCellera Biologics Inc. $ABCL - MarketBeat
AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 - Yahoo Finance
AbCellera Biologics Inc Doses First Patients in Phase 2 Trial for ABCL635 - TradingView — Track All Markets
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5.6%Should You Sell? - MarketBeat
AbCellera begins phase 2 trial of non-hormonal menopause treatment By Investing.com - Investing.com Nigeria
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause - BioSpace
AbCellera begins phase 2 trial of non-hormonal menopause treatment - Investing.com
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL6 - PharmiWeb.com
AbCellera (ABCL) Advances Clinical Trial for Menopause Treatment - GuruFocus
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up on Analyst Upgrade - MarketBeat
Bear Alert: Is AbCellera Biologics Inc stock forming a triangle patternJuly 2025 Drop Watch & Smart Allocation Stock Tips - baoquankhu1.vn
AbCellera Biologics (NASDAQ:ABCL) Rating Increased to Hold at Wall Street Zen - MarketBeat
A Look At AbCellera Biologics (ABCL) Valuation After Bruker Settlement And Board Appointment - simplywall.st
Will AbCellera Biologics Inc. stock return to pre crisis levels2025 Pullback Review & Weekly Watchlist of Top Performers - ulpravda.ru
Can AbCellera Biologics Inc. stock maintain operating marginsJuly 2025 Macro Moves & Safe Capital Growth Plans - Улправда
AbCellera Biologics (ABCL) Is Up 20.8% After Bruker Settlement Win And Board AdditionWhat's Changed - simplywall.st
How AbCellera Biologics Inc. stock performs in weak economyJuly 2025 WrapUp & Safe Capital Growth Plans - Улправда
Can AbCellera Biologics Inc. stock hit analyst price targetsMarket Correction Analysis & Maximize Returns With Insights - Улправда
AbCellera (ABCL) Loses Chief Commercial Officer to Viking Therap - GuruFocus
AbCellera Biologics (NASDAQ:ABCL) Trading Up 9.2%Still a Buy? - MarketBeat
AbCellera settles patent litigation with Bruker over microfluidic device tech - MSN
AbCellera Biologics (NASDAQ:ABCL) Cut to Sell at Wall Street Zen - MarketBeat
Is AbCellera Biologics Inc a good long term investmentMid Cap Growth Trends & These 3 Stocks Could Change Your Portfolio - earlytimes.in
MACD Cross Could Confirm Trend in Sancode Technologies LimitedEmerging Market Stocks & Unlock Patterns Humans Can’t See - earlytimes.in
Update Recap: How AbCellera Biologics Inc stock performs in weak economyExit Point & Real-Time Volume Analysis Alerts - moha.gov.vn
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of "Hold" by Analysts - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Upgraded at Wall Street Zen - MarketBeat
We're Not Worried About AbCellera Biologics' (NASDAQ:ABCL) Cash Burn - Yahoo Finance
AbCellera: Losing Its Undeserved Premium (NASDAQ:ABCL) - Seeking Alpha
AbCellera Appoints Dr. Stephen Quake to Board - MSN
Why AbCellera Biologics Inc. stock is in analyst buy zoneMarket Activity Report & High Accuracy Investment Entry Signals - Улправда
Can AbCellera Biologics Inc. stock beat analyst upgrades2025 Trading Volume Trends & Verified Stock Trade Ideas - Улправда
Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? - MSN
AbCellera Biologics (STU:8QQ) EV-to-OCF : -6.77 (As of Dec. 22, 2025) - GuruFocus
AbCellera Gets $36M In Cell Research Patent Settlement - Law360
Buyout Rumor: How AbCellera Biologics Inc. stock performs in weak economyCEO Change & Weekly High Potential Alerts - DonanımHaber
Published on: 2025-12-19 14:45:34 - Улправда
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):